Rein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trial

Rein Therapeutics (RNTX) announced that the UK Medicines and Healthcare products Regulatory Agency, MHRA, has authorized the Company to initiate its Phase 2 “RENEW” clinical trial of LTI-03, the Company’s lead drug candidate for idiopathic pulmonary fibrosis. Brian Windsor, Chief Executive Officer of Rein Therapeutics, commented, “This MHRA approval marks an important milestone not only for Rein, but also for patients living with IPF. We are now working towards patient recruitment in the U.K., advancing LTI-03 into the next stage of development. Our approach is designed not only to slow disease progression, but also to preserve, and potentially restore, the lung cells that are critical to everyday breathing and quality of life. We believe LTI-03 has the potential to transform outcomes for patients while also creating substantial value for our shareholders.”